Astellas announce first dosing of patient in late-stage menopause trial
Astellas Pharma has announced the initiation and dosing of the first patient in their SKYLIGHT1 Phase III pivotal trial for fezolinetant. The investigational oral, non-hormonal compound is being studied for the treatment of moderate-to-severe menopause related vasomotor symptoms (VMS), such as hot flashes and night sweats. The first trials of the programme will evaluate the efficacy